Medtronic (MDT) Earnings Date & Reports

Key Takeaways

• Medtronic plc reported first-quarter fiscal 2027 revenue of $9.756 billion, up 13.7% on both a reported and organic basis, topping consensus estimates near $9.55 billion.
• Non-GAAP diluted earnings per share (EPS) came in at $1.45, ahead of the $1.39 consensus and up 15.1% year over year; GAAP diluted EPS was $1.14.
• The company raised its full-year fiscal 2027 outlook, lifting organic revenue growth guidance to 7.25%–7.75% and non-GAAP EPS guidance to $5.94–$6.00.
• Growth was broad-based across all four segments, led by an 18.9% organic increase in the Cardiovascular Portfolio and an 88% surge in Cardiac Ablation Solutions.
• An extra fiscal week contributed roughly $570 million, or about 670 basis points, to first-quarter organic growth.

Earnings Context and Why It Matters

Medtronic's first-quarter fiscal 2027 report matters because it is the clearest read yet on whether the medical device giant can sustain the momentum that has re-energized its growth story. As the world's largest pure-play medtech company, Medtronic's performance is often viewed as a barometer for elective procedure volumes, hospital capital spending, and innovation-driven demand across cardiology, neurology, and surgery. Coming off a strong fiscal 2026, investors were watching whether newer platforms such as pulsed field ablation, renal denervation, and surgical robotics could broaden growth beyond a few standout businesses. The results, alongside an upward revision to full-year guidance, signal that management sees durable, diversified demand rather than a single-quarter spike.

Reported Results

For the first quarter of fiscal 2027, which ended July 31, 2026, Medtronic reported worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis, exceeding analyst consensus of roughly $9.55 billion. Results included an extra fiscal week that management estimated contributed approximately $570 million, or about 670 basis points, to organic growth.

On a GAAP basis (Generally Accepted Accounting Principles, the standard accounting rules for reported financials), diluted EPS was $1.14, up 40.7% from $0.81 a year earlier. On a non-GAAP basis, which excludes items such as intangible asset amortization and restructuring costs, diluted EPS was $1.45, up 15.1% year over year and $0.06 above the consensus estimate of $1.39. Non-GAAP operating margin expanded 10 basis points to 23.7%.

Performance was broad-based across the portfolio. The Cardiovascular Portfolio grew 18.9% organically to $3.927 billion, driven by 29.1% organic growth in Electrophysiology Therapies, including 88% growth in Cardiac Ablation Solutions. Neuroscience revenue rose 9.3% organically to $2.678 billion, Medical Surgical increased 10.2% organically to $2.279 billion, and the Diabetes business grew 14.9% organically to $843 million.

Management also raised fiscal 2027 guidance, lifting organic revenue growth expectations to 7.25%–7.75% from a prior 6.75%–7.25% and raising non-GAAP diluted EPS guidance to $5.94–$6.00 from $5.90–$6.00.

AI Screener

For investors looking to monitor opportunities across the medical device sector and beyond, Tickeron's AI Screener offers an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and emerging opportunities more efficiently than manual screening, making it a practical companion for earnings-season research. Explore the AI Screener to refine your market watchlist today.

Market Reaction and Investor Sentiment

Investors responded positively to the report, with MDT shares rising roughly 5% in pre-market trading following the announcement, according to financial media coverage. The combination of a revenue and EPS beat, strong segment performance, and a guidance increase helped reinforce confidence in Medtronic's growth trajectory. Sentiment was tempered somewhat by recognition that the extra fiscal week inflated headline growth, and by management's guidance implying a more moderate second-quarter pace. Still, the breadth of the beat, particularly the accelerating momentum in Cardiac Ablation Solutions and solid contributions from newer growth platforms, was viewed as evidence that Medtronic's expansion is not dependent on any single product line.

Forward Outlook and Key Factors to Monitor

Following the first-quarter report, several factors will shape how investors assess Medtronic through the remainder of fiscal 2027. The most immediate consideration is whether organic growth can hold up without the benefit of the extra selling week. Management has signaled that second-quarter growth will moderate, and investors will be watching whether the underlying demand trajectory remains intact.

The Cardiac Ablation Solutions franchise remains a central watch item. Its 88% worldwide growth in the quarter underscores strong adoption of pulsed field ablation technology, but the business is now lapping increasingly difficult comparisons. Sustained share gains in the U.S. market will be key to the narrative.

Costs and margins also deserve attention. While adjusted operating margin expanded slightly, management has noted that fast-growing businesses such as Diabetes and Cardiac Ablation Solutions carry lower margins, creating a mix headwind. Foreign exchange is expected to be a modest full-year headwind, and the company is reinvesting in commercial expansion and acquisitions.

Finally, portfolio moves will matter. Medtronic announced a strategic partnership with Cornerstone Robotics, an investment in Pi-Cardia, and the completion of the Scientia Vascular and SPR Therapeutics acquisitions during the quarter. The planned separation of the Diabetes business also remains a structural catalyst to monitor, as its eventual structure could influence both reported results and investor valuation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations